# Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct05573724/  
OnCo record `nct05573724` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is completed.

## Summary

The registry lists NCT05573724 as completed, last updated 2024-06-18. Enrolment is 16 actual participants. Interventions: AZD5305, Itraconazole. Primary measures include Part A: Area under the concentration-time curve from time zero to infinity (AUCinf); Part A: AUC from time zero to time of last measurable concentration (AUClast). No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-10-06
- Registry id: NCT05573724
- Phase: 1
- Setting: A Non-randomized, Open-label, Fixed-sequence Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD5305 in Patients With Advanced Solid Malignancies
- Sponsor: AstraZeneca
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT05573724: https://clinicaltrials.gov/study/NCT05573724

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct05573724.json